- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.04. | Carmell Corporation: Carmell Announces Successful Closing of $3.0 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 04.04. | Carmell Corporation: Carmell Announces $3.0 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 01.04. | Carmell Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 01.04. | Carmell Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Carmell Corporation: Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction | 1 | GlobeNewswire (USA) | ||
| 20.03. | Carmell looks to sell Axolotl Biologix | 1 | Seeking Alpha | ||
| 20.03. | Carmell Corporation: Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary | 55 | GlobeNewswire (Europe) | PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today... ► Artikel lesen | |
| 18.03. | Carmell Corporation: Carmell to Host Investor Webinar, "Unveiling the Secretome: On the Eve of Product Launch" Featuring Key Opinion Leaders in the Medical Aesthetics Field | 1 | GlobeNewswire (USA) | ||
| 26.02. | Carmell Corporation: Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024 | 1 | GlobeNewswire (USA) | ||
| 17.01. | Carmell Corp - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | Carmell Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 29.11.23 | Carmell CEO buys shares worth over $15.5k - filing | 1 | Seeking Alpha | ||
| 16.11.23 | Carmell Corporation: Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.11.23 | Carmell Corp - 8-K, Current Report | - | SEC Filings | ||
| 15.11.23 | Carmell Corp - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 14.11.23 | Carmell Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.09.23 | Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics | 295 | GlobeNewswire (Europe) | PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX) ("Carmell"), a regenerative care company, today announced the completion of post-merger integration with Flagstaff-based... ► Artikel lesen | |
| 14.07.23 | Alpha Healthcare Acquisition Corp. III Announces Successful Closing of Business Combination with Carmell Therapeutics Corporation | 575 | Business Wire | NEW YORK & PITTSBURGH--(BUSINESS WIRE)--Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the successful... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -1,27 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,020 | +25,00 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,825 | -2,02 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,355 | +2,83 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,420 | +0,96 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| ONCOLYTICS BIOTECH | 1,060 | +2,91 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,430 | -5,27 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,999 | +9,30 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 9,250 | -0,75 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | +0,17 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,020 | +3,09 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,160 | +2,84 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,140 | -2,04 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,780 | +4,12 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,750 | +1,56 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
CARMELL CORPORATION gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,130 (+6,95 %) liegt der Kurs bei 2,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
